1Swisher SG, Roth JA. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am, 2002, 11: 521-535.
2Huang X, Lin T, Gu J, et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther, 2002, 9: 1379-1386.
3Iwakami SI, Setoguchi Y, Saijo Y, et al. Replication-deficient adenovirus- mediated transfer of B7-1 (CD80) cDNA induces anti-tumour immunity in isolated human lung cancer. Respirology, 2001, 6: 135-144.
4Hubberstey AV, Pavliv M, Parks RJ. Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Ther, 2002, 9: 321-329.
5Schwarzenberger P, Huang W, Oliver P, et al. Poly-L-lysine- based molecular conjugate vectors: a high efficiency gene transfer system for human progenitor and leukemia cells. Am J Med Sci, 2001, 321: 129-136.
6Orson FM, Song L, Gautam A, et al. Gene delivery to the lung using protein/poly-ethylenimine/plasmid complexes. Gene Ther, 2002, 9: 463-471.
7Schuler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase Ⅱ study. J Clin Oncol, 2001, 19: 1750-1758.
8Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res, 2003, 9: 93-101.
9Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther, 2002, 9: 1207-1213.
